Table 2.
Ref. | Major conclusions |
Taketani et al[21] | p53 partners with ATF3 in maximal induction of DR5 upon |
DNA damage | |
Wei et al[25] | ATF3 binds mutant p53 and inhibits its oncogenic function |
Nishida et al[30] | High expression of miRNA-125b predicts poor survival in CRC. miRNA-125 decreases p53 expression |
Kim et al[34,35] | Loss of p53 de-represses Wnt pathway and EMT transition through miRNA-34 |
López et al[41] | p53 mutations occur in 54% of sporadic CRC |
Russo et al[42] | p53 mutations correlate with the site, biologic behaviour and outcome of CRC |
Iacopetta et al[44] | p53 mutations that lose transactivational ability are more common in advanced CRC and associated with poor survival |
EMT: Epithelial-mesenchymal transition; CRC: Colorectal cancer.